Numab Therapeutics
Latest round
- Series C
Last raised
- Jan 2025
Total raised
- $194M
Investors
- 11
About Numab Therapeutics
Founded in 2011 and headquartered in Zurich, Switzerland, Numab Therapeutics AG specializes in immunotherapy development.Numab Therapeutics AG specializes in developing multi-specific antibody-based immunotherapies with a focus on inflammation and cancer.-Cap™ and MATCH™, aiding in the creation of tailored therapeutic options. Notably, their lead candidate NM26 targets IL-4Ra and IL-31 for atopic dermatitis and related disorders.Numab Therapeutics AG generates revenue through strategic collaborations with pharmaceutical companies for therapy development and commercialization. Their revenue model is primarily B2B, relying on partnerships that fund research and clinical development in return for licensing rights or profit-sharing agreements.Numab Therapeutics AG plans to further its growth by launching new products, including advancing NM26 through clinical trials. The company aims to expand its market presence in Europe, North America, and Asia by strategically collaborating with pharmaceutical partners and advancing their therapeutic offerings in these regions.
Who invested in Numab Therapeutics
11 investors across 4 rounds
See all investors in Numab Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Numab Therapeutics
Who invested in Numab Therapeutics?
Numab Therapeutics has 11 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Numab Therapeutics raised?
Numab Therapeutics has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Numab Therapeutics last raise money?
Numab Therapeutics's most recent round on record is a Series C, in Jan 2025.
What does Numab Therapeutics do?
Founded in 2011 and headquartered in Zurich, Switzerland, Numab Therapeutics AG specializes in immunotherapy development.
Where is Numab Therapeutics headquartered?
Numab Therapeutics is headquartered in Switzerland.
Which VCs invest in companies like Numab Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Numab Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Numab Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.